|
21 Oct 2021 |
Daiichi Sankyo Announces Development Progress of mRNA COVID-19 Vaccine in Japan
|
|
21 Oct 2021 |
Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
|
|
21 Oct 2021 |
FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
|
|
21 Oct 2021 |
First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
|
|
20 Oct 2021 |
AmMax Bio Announces Positive Interim Phase 2 Results of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
|
|
20 Oct 2021 |
F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
|
|
20 Oct 2021 |
Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer
|
|
20 Oct 2021 |
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
|
|
20 Oct 2021 |
Axalbion Announces First Patients Treated in Phase 2 Clinical Trial in Chronic Cough with AX-8, a Novel TRPM8 Agonist
|
|
20 Oct 2021 |
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress
|
|
20 Oct 2021 |
HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy
|
|
20 Oct 2021 |
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
|
|
20 Oct 2021 |
Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis
|
|
20 Oct 2021 |
Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021
|
|
20 Oct 2021 |
Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Acute Myeloid Leukemia
|
|
20 Oct 2021 |
ONO PHARMA USA Announces Initiation of Phase 1 Study of ONO-4685, an Anti-PD-1/CD3 Bispecific Antibody, in Patients with Relapsed or Refractory T-cell Lymphoma in the U.S
|
|
20 Oct 2021 |
Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009
|
|
20 Oct 2021 |
COUR Pharmaceuticals Announces First in Human Dosing in Proof-of-Concept Trial of CNP-201 to Treat Peanut Allergy
|
|
20 Oct 2021 |
NeoTX Announces First Patient Enrolled In Phase 2a Clinical Trial Of Naptumomab Estafenatox (NAP), Its Lead Tumor Targeted Superantigen (TTS) Candidate, In Combination With Docetaxel In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
|
|
20 Oct 2021 |
Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)
|
